ANI Pharmaceuticals, Inc. (ANIP)
72.61
-1.14
(-1.55%)
USD |
NASDAQ |
Oct 23, 16:00
72.61
0.00 (0.00%)
After-Hours: 20:00
ANI Pharmaceuticals Enterprise Value : 1.903B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.903B |
| October 22, 2026 | 1.929B |
| October 21, 2026 | 1.894B |
| October 20, 2026 | 1.904B |
| October 19, 2026 | 1.901B |
| October 16, 2026 | 1.895B |
| October 15, 2026 | 1.895B |
| October 14, 2026 | 1.846B |
| October 13, 2026 | 1.862B |
| October 12, 2026 | 1.925B |
| October 09, 2026 | 1.932B |
| October 08, 2026 | 1.888B |
| October 07, 2026 | 1.887B |
| October 06, 2026 | 1.878B |
| October 05, 2026 | 1.902B |
| October 02, 2026 | 1.893B |
| October 01, 2026 | 1.911B |
| September 30, 2026 | 1.904B |
| September 29, 2026 | 1.903B |
| September 28, 2026 | 1.954B |
| September 25, 2026 | 1.935B |
| September 24, 2026 | 1.935B |
| September 23, 2026 | 1.944B |
| September 22, 2026 | 2.024B |
| September 21, 2026 | 2.046B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.984B |
| September 17, 2026 | 1.967B |
| September 16, 2026 | 1.925B |
| September 15, 2026 | 1.891B |
| September 14, 2026 | 1.852B |
| September 11, 2026 | 1.847B |
| September 10, 2026 | 1.876B |
| September 09, 2026 | 1.859B |
| September 08, 2026 | 1.848B |
| September 04, 2026 | 1.871B |
| September 03, 2026 | 1.888B |
| September 02, 2026 | 1.913B |
| September 01, 2026 | 1.887B |
| August 31, 2026 | 1.917B |
| August 28, 2026 | 1.908B |
| August 27, 2026 | 1.923B |
| August 26, 2026 | 1.947B |
| August 25, 2026 | 1.972B |
| August 24, 2026 | 1.938B |
| August 21, 2026 | 1.966B |
| August 20, 2026 | 2.011B |
| August 19, 2026 | 2.027B |
| August 18, 2026 | 2.001B |
| August 17, 2026 | 1.981B |
| August 14, 2026 | 1.993B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.245T |
| Ocular Therapeutix, Inc. | 908.07M |
| Liquidia Corp. | 3.699B |
| Elanco Animal Health, Inc. | 14.64B |
| Harmony Biosciences Holdings, Inc. | 1.653B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 23.00M |
| Revenue (Quarterly) | 266.04M |
| Total Expenses (Quarterly) | 243.04M |
| EPS Diluted (Quarterly) | 1.052 |
| Gross Profit Margin (Quarterly) | 54.97% |
| Profit Margin (Quarterly) | 8.65% |
| Earnings Yield | 6.38% |
| Operating Earnings Yield | 8.33% |
| Normalized Earnings Yield | 5.019 |